Cubist Systematic Strategies, LLC Gracell Biotechnologies Inc. Transaction History

Cubist Systematic Strategies, LLC

  • $15.8 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$2.43 - $10.04 $140,104 - $578,866
57,656 Added 4097.8%
59,063 $592,000
Q3 2023

Nov 14, 2023
SELL
$2.83 - $4.9 $4,728 - $8,187
-1,671 Reduced 54.29%
1,407 $4,000
Q2 2023

Aug 14, 2023
SELL
$1.45 - $6.07 $13,532 - $56,651
-9,333 Reduced 75.2%
3,078 $11,000
Q1 2023

May 15, 2023
BUY
$1.8 - $2.5 $22,339 - $31,027
12,411 New
12,411 $23,000

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email